Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Healthcare | Small Cap
Health Score : 7.84Neuland Laboratories Ltd. demonstrates exceptional financial health, driven by outstanding profitability and remarkable growth. The company excels at converting revenue into profit and is expanding its sales and earnings at a very high rate. Its financial foundation is extremely solid, with very little reliance on debt, which significantly reduces long-term risks. Shareholders have benefited from strong growth in earnings and dividends. The main area of concern is operational efficiency; the company is slow in selling its inventory and collecting payments, and it does not generate as much sales from its assets as it could. While it has an adequate ability to meet its short-term bills, its cash generation from operations is a weaker point. The outlook is positive due to strong growth and profitability, but its future performance also depends on how well it manages its assets.
Health Score : 7.84Neuland Laboratories Ltd. demonstrates exceptional financial health, driven by outstanding profitability and remarkable growth. The company excels at converting revenue into profit and is expanding its sales and earnings at a very high rate. Its financial foundation is extremely solid, with very little reliance on debt, which significantly reduces long-term risks. Shareholders have benefited from strong growth in earnings and dividends. The main area of concern is operational efficiency; the company is slow in selling its inventory and collecting payments, and it does not generate as much sales from its assets as it could. While it has an adequate ability to meet its short-term bills, its cash generation from operations is a weaker point. The outlook is positive due to strong growth and profitability, but its future performance also depends on how well it manages its assets.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
81.36
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
81.16
P/B RATIO
15.76
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
14.57
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
2.10
EV/EBITDA RATIO
48.57
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹23025 as on Sep 1, 2026.
Growth Score : 10.00The company is demonstrating excellent and robust growth across the board. It has achieved very high rates of expansion in its revenue, operating profits, and net income. This rapid growth is a clear indicator of strong market demand for its offerings and successful execution of its business strategy. While projections show some volatility with a dip in 2025, the overall trend points to a powerful growth trajectory, which is a key strength.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 1.49 | 25.24 | 30.9 | -5.26 | 36.97 |
| Operating Profit Growth Rate | -2.04 | 89.58 | 69.6 | -28.51 | 73.41 |
| Earnings Per Share (EPS) Growth | -20.86 | 156.23 | 83.52 | -13.32 | 39.94 |
| Asset Growth Rate | 4.38 | 14.24 | 16.01 | 18.93 | 34.4 |
| Net Income Growth Rate | -20.99 | 156.25 | 82.93 | -13.33 | 40 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | J B Chemicals & Pharmaceuticals Ltd | 8.14 | 54.51 | Overvalued | 1107.00 | 41.98 | 709.00 |
| 2 | Gland Pharma Ltd | 7.91 | 46.11 | Overvalued | 1630.00 | 78.78 | 1027.00 |
| 3 | Neuland Laboratories Ltd | 7.84 | 81.16 | Highly Overvalued | 574.00 | 283.01 | 364.00 |
| 4 | Granules India Ltd | 7.73 | 34.87 | Highly Overvalued | 1185.00 | 16.17 | 595.00 |
| 5 | Ajanta Pharma Ltd | 7.72 | 41.47 | Neutral | 1395.00 | 75.78 | 1056.00 |
| 6 | Alembic Pharmaceuticals Ltd | 7.60 | 24.58 | Undervalued | 1118.00 | 32.58 | 671.00 |
| 7 | Emcure Pharmaceuticals Ltd | 7.40 | 37.86 | Neutral | 1865.00 | 38.64 | 941.00 |
| 8 | Syngene International Ltd | 7.16 | 51.15 | Neutral | 918.00 | 7.55 | 317.00 |
| 9 | ERIS Lifesciences Ltd | 7.15 | 29.07 | Neutral | 1120.00 | 17.61 | 648.00 |
| 10 | Piramal Pharma Ltd | 5.83 | -87.02 | Neutral | 922.00 | 5.26 | -326.00 |
| 11 | Jubilant Pharmova Ltd | 5.71 | 36.27 | Neutral | 1260.00 | 1.25 | 398.00 |
| 12 | Natco Pharma Ltd | 5.69 | 10.72 | Neutral | 1436.00 | 71.55 | 1418.00 |
| 13 | Wockhardt Ltd | 5.07 | 141.16 | Neutral | 652.00 | 19.51 | 199.00 |
| 14 | Pfizer Ltd | 3.45 | 46.48 | Neutral | -82.00 | 157.92 | 300.00 |
| 15 | Procter & Gamble Health Ltd | 3.45 | 29.33 | Neutral | 466.00 | 215.00 | 357.00 |
| 16 | Sanofi India Ltd | 3.45 | 17.56 | Neutral | 491.00 | 134.52 | 413.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Neuland Laboratories Ltd is a pharmaceutical manufacturer focusing on Active Pharmaceutical Ingredients (APIs), custom manufacturing solutions (CMS), and contract research and manufacturing services (CRAMS). It serves global innovator and generic companies, specializing in complex chemistry and niche therapeutic areas with a strong R&D focus and compliance. The company operates globally.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Neuland Laboratories Ltd's P/E ratio (TTM) is 81.36, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Neuland Laboratories Ltd's P/B ratio is 15.76, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Neuland Laboratories Ltd's P/S ratio is 14.57, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Neuland Laboratories Ltd's PEG ratio is 2.10.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Neuland Laboratories Ltd's EV/EBITDA ratio is 48.57.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Neuland Laboratories Ltd's ROE is 19.41%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Neuland Laboratories Ltd's ROA is 19.59%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Neuland Laboratories Ltd's ROCE is 27%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Neuland Laboratories Ltd's operating margin is 28.37%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Neuland Laboratories Ltd's net margin is 17.99%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Neuland Laboratories Ltd's current ratio is 1.95.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Neuland Laboratories Ltd's debt-to-equity ratio is 0.14.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Neuland Laboratories Ltd's interest coverage ratio is 21.38.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Neuland Laboratories Ltd's DPS is ₹34.05.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Neuland Laboratories Ltd's EPS is 39.94.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹23025. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1984
Headquarters: Hyderabad, Telangana
Core Offerings: Active Pharmaceutical Ingredients (APIs), Custom Manufacturing Solutions (CMS), Peptides, Advanced Intermediates, Contract Research & Manufacturing Services (CRAMS)
Stock Listing: NSE (NEULANDLAB), BSE (524558)
Promoter: Davuluri Rama Mohan Rao & family
Neuland Laboratories Ltd was founded in 1984 by Dr. D.R. Rao. The company commenced commercial production in 1994 and went public with an IPO in 1995. Over the years, it has significantly expanded its manufacturing facilities and R&D capabilities, focusing on developing and manufacturing complex APIs and providing custom manufacturing solutions to global pharmaceutical innovators. Neuland has established itself as a reliable CDMO partner with a strong focus on quality and compliance.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Active Pharmaceutical Ingredients (API) | 57% | N/A (generally lower than CMS) |
| Custom Manufacturing Solutions (CMS) | 43% | N/A (generally higher than API) |
Active Pharmaceutical Ingredients (APIs): Develops and manufactures a diverse portfolio of generic APIs for various therapeutic areas, serving regulated markets globally. It focuses on niche and complex molecules, leveraging strong in-house R&D capabilities and backward integration.
Custom Manufacturing Solutions (CMS): Provides contract development and manufacturing services (CDMO) to innovator pharmaceutical companies. This involves late-stage clinical to commercial supply for complex molecules, including peptides, generating higher margins and long-term partnerships.
Dr. D.R. Rao: Founder & Chairman Emeritus. A visionary leader who established Neuland Labs, guiding its journey into API and CMS manufacturing. Saharsh Davuluri: Vice Chairman & Managing Director. Instrumental in driving the company's operational excellence, strategic initiatives, and overall growth since joining. Davuluri Sucheth Rao: Vice Chairman & Managing Director. Leads the company's innovation, research & development, and business development efforts for new opportunities.
Neuland Pharma Research Private Limited (India)
Neuland Laboratories Inc. (USA)
Neuland Pharmaceutical Services, LLC (USA)
No major recent corporate actions on record.
The Neuland Laboratories Ltd share price today is ₹23025 on NSE (NEULANDLAB), as of 26 Sept 2026.
As of 25 Sept 2026, Neuland Laboratories Ltd share price is ₹23025, with previous close ₹23025. Today's range is ₹23025 to ₹23025. The 52-week range is ₹11500 to ₹24225.
As of today, Neuland Laboratories Ltd's market cap is ₹29,472 crore (Large Cap).
Neuland Laboratories Ltd's current P/E ratio is 81.36, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 32.
Neuland Laboratories Ltd's current P/B ratio is 15.76.
Neuland Laboratories Ltd's current dividend yield is 0.15%. Last dividend of ₹10.00 per share was declared on 02-Aug-2023.
Neuland Laboratories Ltd's EPS (TTM) is ₹39.94.
Neuland Laboratories Ltd is a pharmaceutical manufacturer focusing on Active Pharmaceutical Ingredients (APIs), custom manufacturing solutions (CMS), and contract research and manufacturing services (CRAMS). It serves global innovator and generic companies, specializing in complex chemistry and niche therapeutic areas with a strong R&D focus and compliance. The company operates globally.
Neuland Laboratories Ltd is promoted by Davuluri Rama Mohan Rao & family, holding 32.63% as of 25 Sept 2026.
Neuland Laboratories Ltd is listed on NSE (NEULANDLAB) and BSE (524558). Its next quarterly results are expected on August 2024.
Current Ratios
Quick Ratios
